Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Aug;15(4):e727-e734.
doi: 10.1016/j.clgc.2016.11.001. Epub 2016 Dec 1.

Comprehensive Genomic Analysis of Metastatic Mucinous Urethral Adenocarcinoma Guides Precision Oncology Treatment: Targetable EGFR Amplification Leading to Successful Treatment With Erlotinib

Alan H Bryce  1 , Mitesh J Borad  2 , Jan B Egan  3 , Rachel M Condjella  4 , Winnie S Liang  5 , Rafael Fonseca  2 , Ann E McCullough  6 , Katherine S Hunt  7 , Nicole R Ritacca  4 , Michael T Barrett  8 , Maitray D Patel  9 , Scott W Young  9 , Alvin C Silva  9 , Thai H Ho  2 , Thorvardur R Halfdanarson  2 , Melissa L Stanton  6 , John Cheville  10 , Scott Swanson  11 , Daniel E Schneider  11 , Robert R McWilliams  12 , Angela Baker  5 , Jessica Aldrich  5 , Ahmet Kurdoglu  5 , Tyler Izatt  5 , Alexis Christoforides  5 , Irene Cherni  5 , Sara Nasser  5 , Rebecca Reiman  5 , Lori Cuyugan  5 , Jacquelyn McDonald  5 , Jonathan Adkins  5 , Stephen D Mastrian  5 , Daniel D Von Hoff  5 , David W Craig  5 , A Keith Stewart  2 , John D Carpten  5
Affiliations
Case Reports

Comprehensive Genomic Analysis of Metastatic Mucinous Urethral Adenocarcinoma Guides Precision Oncology Treatment: Targetable EGFR Amplification Leading to Successful Treatment With Erlotinib

Alan H Bryce et al. Clin Genitourin Cancer. 2017 Aug.
No abstract available

Keywords: EGFR; Exome; Genome; Transcriptome; Urethral adenocarcinoma.

PubMed Disclaimer

Conflict of interest statement

Disclosure

The authors have stated that they have no conflict of interest.

Figures

Figure 1
Figure 1
Treatment and Response Course With Representative IHC Staining of MAU Tissues. (A) CEA Levels Over Time Relative to Treatments Received. CEA Levels Were Not Obtained Before March 2014. Computed Tomographic Scans Before Enrollment Onto Clinical Trial NCT02091141 in August 2015 and Demonstrated Continuing Response to EGFR Inhibitor Erlotinib in August 2016. Red Ring Indicates Area of Tumor Shrinkage. (B) Representative IHC Staining of Archival MAU Tissues. Intensity and Proportion of Positive Cells for EGFR IHC Were Recorded. Staining Intensity was Scored From 0 to 3+ and Was Defined as Follows: 0, No Staining or Weak Staining in < 10%; 1+, Weak Staining in > 10%; 2+, Moderate Staining; 3+, Strong Staining Based on Staining Score. Tumors With 1+, 2+, or 3 + Expression Were Interpreted as Positive, and Tumors With No Expression (0 Score) Were Interpreted as Negative. Cytoplasmic or Membranous Distribution of Positive Staining Was Also Recorded and Evaluated at High Magnification. Hematoxylin and Eosin and EGFR IHC Staining at 20× Magnification of Case Study MAU With 3+ Positive Staining With Cytoplasmic and Membranous EGFR Expression, Archival Patient 1 MAU Sample With Focal Membranous Positivity, and Archival Patient 2 MAU Sample With 3 + Positive Staining With Cytoplasmic and Membranous EGFR Expression Abbreviations: CEA = carcinoembryonic antigen; EGFR = epidermal growth factor receptor; IHC = immunohistochemistry; MAU = mucinous adenocarcinoma of urethra.
Figure 2
Figure 2
Genomewide Copy Number Alterations. Red Indicates Copy Number Gain; Green, Copy Number Loss. Note Focal Amplification of EGFR on Chromosome 7
See this image and copyright information in PMC

References

    1. Visser O, Adolfsson J, Rossi S, et al. Incidence and survival of rare urogenital cancers in Europe. Eur J Cancer 2012; 48:456–64. - PubMed
    1. Swartz MA, Porter MP, Lin DW, Weiss NS. Incidence of primary urethral carcinoma in the United States. Urology 2006; 68:1164–8. - PubMed
    1. Rabbani F Prognostic factors in male urethral cancer. Cancer 2011; 117:2426–34. - PubMed
    1. Raspollini MR, Carini M, Montironi R, Cheng L, Lopez-Beltran A. Mucinous adenocarcinoma of the male urethra: a report of two cases. Anal Quant Cytopathol Histpathol 2015; 37:267–72. - PubMed
    1. Dimitroulis D, Patsouras D, Katsargyris A, Charalampoudis P, Anastasiou I, Kouraklis G. Primary enteric-type mucinous adenocarcinoma of the urethra in a patient with ulcerative colitis. Int Surg 2014; 99:669–72. - PMC - PubMed

Publication types